Premium
COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS
Author(s) -
Tarantelli C.,
Lange M.,
Gaudio E.,
Cascione L.,
Spriano F.,
Kwee I.,
Arribas A.,
Rinaldi A.,
Jourdan T.,
Berthold M.,
Margheriti F.,
Gritti G.,
Rossi D.,
Stathis A.,
Liu N.,
Zucca E.,
Politz O.,
Bertoni F.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.127_2630
Subject(s) - venetoclax , mantle cell lymphoma , cancer research , panobinostat , ibrutinib , bendamustine , medicine , lymphoma , pharmacology , chemistry , chronic lymphocytic leukemia , rituximab , immunology , leukemia , histone deacetylase , biochemistry , gene , histone
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom